Methods and devices for management of fluids during skin graft transplantation are disclosed. In one aspect of the invention, absorbent substrates for transplanting skin grafts are disclosed having a surface adapted to contact at least one excised skin graft and engage said graft for removal from a donor site; a sealing member at least partially surrounding an absorbent material disposed within the enclosure; wherein at least a portion of the skin-contacting surface is porous and in fluid communication with the absorbent layer to capture fluids.
|
40. An absorbent substrate for transplanting a skin graft, comprising:
a base layer having a plurality of pores and having at least one adhesive site adapted to contact at least one excised skin graft and capture said graft for removal from a donor site, said pores having an average width in a range of about 1 nanometer to about 10 micrometers;
a sealing member peripherally joined to the base layer and defining an enclosure therebetween;
an absorbent material disposed within the enclosure; and
at least a first wicking layer and a second wicking layer disposed in the enclosure between the base layer and the absorbent material, the second wicking layer being disposed adjacent to the sealing member and the first and second wicking layers being joined together to form a seal that encloses the absorbent material;
wherein at least a portion of the base layer is in fluid communication with the absorbent material to capture fluids.
1. An absorbent substrate for transplanting a skin graft, comprising:
a base layer having a plurality of pores and having at least one adhesive site adapted to contact at least one excised skin graft and capture said graft for removal from a donor site;
a sealing member peripherally joined to the base layer and defining an enclosure therebetween;
an absorbent material disposed within the enclosure; and
at least a first wicking layer and a second wicking layer disposed in the enclosure between the base layer and the absorbent material, said first wicking layer having a grain structure adapted to transport fluid in a lateral direction along a surface thereof, the second wicking layer being disposed adjacent to the sealing member and the first and second wicking layers being joined together to form a seal that encloses the absorbent material;
wherein at least a portion of the base layer is in fluid communication with the absorbent material to capture fluids.
2. The substrate of
3. The substrate of
5. The substrate of
7. The substrate of
8. The substrate of
9. The substrate of
11. The substrate of
12. The substrate of
13. The substrate of
15. The substrate of
17. The substrate of
18. The substrate of
19. The substrate of
20. The substrate of
21. The substrate of
22. The substrate of
23. The substrate of
24. The substrate of
25. The substrate of
26. The substrate of
27. The substrate of
28. The substrate of
29. The substrate of
30. The substrate of
33. The substrate of
35. The substrate of
36. The substrate of
37. The substrate of
38. The substrate of
39. The substrate of
42. The substrate of
43. The substrate of
44. The substrate of
|
This application claims priority to U.S. Provisional Patent Application No. 61/860,822, filed Jul. 31, 2013 entitled “Absorbent Substrates For Harvesting Skin Grafts”, and U.S. Provisional Application No. 61/782,385, filed Mar. 14, 2013, entitled “Absorbent Dressing With Hybrid Drape”, the disclosures of which are incorporated by reference in their entirety.
The present invention relates generally to medical treatment systems and, more particularly, but not by way of limitation, to absorbent dressings, systems, and methods for harvesting and transplanting skin grafts.
Skin is the largest organ of the human body, representing approximately 16% of a person's total body weight. Because it interfaces with the environment, skin has an important function in body defense, acting as an anatomical barrier from pathogens and other environmental substances. Skin also provides a semi-permeable barrier that prevents excessive fluid loss while ensuring that essential nutrients are not washed out of the body. Other functions of skin include insulation, temperature regulation, and sensation. Skin tissue may be subject to many forms of damage, including burns, trauma, disease, and depigmentation.
Skin grafts are often used to repair such skin damage. Skin grafting is a surgical procedure in which a section of skin is removed from one area of a person's body (autograft), removed from another human source (allograft), or removed from another animal (xenograft), and transplanted to a recipient site of a patient, such as a wound site. As with any surgical procedure, skin grafting involves certain risks. Complications may include graft failure, rejection of the skin graft, bleeding, fluid accumulation or infection at either the donor or recipient site. Additionally, when an autograft is taken from one area of a person's body to produce the graft, some degree of trauma occurs at the donor site. If the recipient site is a large wound or otherwise damaged skin region, the trauma at the donor site can be significant.
Techniques have been developed for harvesting a large number of smaller grafts, e.g., so-called micrografts, to reduce the trauma at the donor site. By removing only a fraction of the skin at a donor site and leaving regions of healthy skin surrounding the excised regions, a large amount of skin for transplantation can be obtained with less discomfort. Micrograft harvesting can also reduce the healing time and risk of infection.
Harvesting of skin grafts can be accomplished in many different ways. One common technique for harvesting a skin graft involves the application of suction to separate a surface portion of the skin, e.g., the epidermis and a basal cell layer, from the underlying dermis. Harvesting of suction blisters typically also involves a heat source to facilitate blister formation.
Various devices are available for generating and harvesting micrografts. For example, the Cellutome™ skin harvester is available from Kinetic Concepts, Inc. of San Antonio, Tex. The Cellutome™ system includes a head that provides a source of reduced pressure (vacuum), and optionally a heater element, and a harvester configured for placement on a target region of a patient's skin. The harvester is further adapted to form a sealing engagement with the head such that the target region of skin is embraced within an evacuated chamber. The Cellutome™ harvester further includes at least one alignment plate having a plurality of holes through which skin blisters can be raised in the presence of negative pressure; and a cutting plate having at least one cutting surface for cleaving skin blisters after they are formed within the chamber.
Typically, micrograft harvesters rely upon a support or substrate to lift the excised blisters from the device. The substrate is then applied to a recipient site so that the plurality of micrografts can be assimilated as transplanted tissue. Ideally, the grafts will expand and coalesce to complete the healing process.
Methods and devices for management of fluids during skin graft transplantation are disclosed. In one aspect of the invention, absorbent substrates for transplanting skin grafts are disclosed having a surface adapted to contact at least one excised skin graft and engage said graft for removal from a donor site; a sealing member at least partially surrounding an absorbent material disposed within the enclosure; wherein at least a portion of the skin-contacting surface is porous and in fluid communication with the absorbent layer to capture fluids.
In one embodiment of the invention, absorbent substrates for transplanting skin grafts are disclosed including a base layer having a surface adapted to contact at least one excised skin graft and to engage said graft for removal from a donor site; a sealing member peripherally joined to the base layer and defining an enclosure therebetween; and an absorbent material disposed within the enclosure; wherein at least a portion of the base layer is porous and in fluid communication with the absorbent layer to capture fluids.
In certain embodiments the substrate includes a base layer configured for positioning in a chamber of a skin graft harvesting device and, optionally, the base layer is further configured to capture a plurality of skin grafts at the same time.
The base layer of the absorbent substrate preferably includes a biocompatible material, e.g., a material selected from the group of silicones, silicone gels, soft silicones, hydrocolloids, hydrogels, polyurethanes, polyurethane gels, polyolefins, polyolefin gels, hydrogenated styrenic copolymers, hydrogenated styrenic copolymer gels, foamed gels and combinations thereof. In some preferred embodiments, the base layer includes silicone.
In certain embodiments, a skin graft contacting portion of the base layer has an average thickness between about 50 microns and about 10 millimeters, preferably in some cases, between about 500 microns (μm) and about 1000 microns (μm). The skin graft contacting portion of the base layer should also be flexible enough to conform to the shape of the harvester and/or the recipient site. For example, the skin graft contacting portion of the base layer can have a stiffness between about 5 Shore OO and about 80 Shore OO.
In another aspect of the invention, the substrate further includes an adhesive associated with at least a part of the base layer to engage the graft. When used with multi-graft or “micrograft” harvesters, the substrate can further include a pattern of adhesive sites on a skin contacting surface of the base layer, each site arranged and configured to engage a corresponding skin graft raised by a skin graft harvesting device. For example, the substrate can carry a pattern of adhesive sites printed on at least a portion of a skin-contacting surface of the base layer. In certain embodiments, the adhesive can include an acrylic adhesive.
In another aspect of the invention, the base layer can include a plurality of openings to provide passageways from fluid transport from the recipient site to the absorbent material. The openings (e.g., pores) can be spaced apart from each other. In certain embodiments, the openings are generally circular. The openings can have an average cross-sectional dimension ranging from about 0.1 nanometers to about 1 millimeter, or preferably an average cross-sectional dimension ranging from about 1 nanometer to about 100 micrometers. In other embodiments, the pores can be elongated or grid-like and their minor dimension can range from about 0.1 nanometers to about 1 millimeter, or preferably from about 1 nanometer to about 100 micrometers.
In another aspect of the invention, the base layer is patterned to define a plurality of skin graft capture sites and the base layer further includes a network of pores disposed between at least some of the capture sites. Again, the pores (disposed between capture sites) can be circular or elongated and have an average cross-section dimension (or a minor dimension, in the case of elongated pores) ranging from about 0.1 nanometers to about 1 millimeter, or preferably ranging from about 1 nanometers to about 100 micrometers.
In yet another aspect of the invention, the substrate can also include at least one wicking layer disposed in the enclosure and adapted to distribute fluid to the absorbent material. For example, the substrate can include at least a first wicking layer disposed in the enclosure between the base layer and the absorbent material. Alternatively, or in addition to the first wicking layer, the substrate can include one or more additional wicking layers (e.g., a second wicking layer) disposed in the enclosure between the absorbent material and the sealing member. In certain embodiments, the first and/or second wicking layer can have a grain structure adapted to wick fluid along a surface of the wicking layer.
In certain embodiments, the absorbent material is a plurality of absorbent layers, and one or more of the additional absorbent layers are positioned in fluid communication between a first wicking layer and a second wicking layer. The substrate can also include at least one intermediate wicking layer disposed in fluid communication between the absorbent layers. In certain embodiments, a peripheral portion of a first wicking layer can be coupled to a peripheral portion of a second wicking layer to provide a wicking layer enclosure surrounding the absorbent layer between the first and the second wicking layers.
In another aspect of the invention, the absorbent material can include a hydrophilic material that is adapted to absorb fluid and the sealing member is liquid impermeable. For example, the sealing member can include a water-impermeable polyurethane component.
In an alternative embodiment, a unitary absorbent structure can be employed rather than a separate base layer and absorbent material. For example, an absorbent substrate according to this embodiment can include an absorbent material having a surface adapted to contact at least one excised skin graft and engage said graft for removal from a donor site. The absorbent material can further include a sealing member surrounding and defining an enclosure for the absorbent material and substantially sealing the absorbent material except for the skin contacting surface; and wherein at least a portion of skin contacting surface of the absorbent material is porous to capture fluids.
In yet another aspect of the invention, the substrate can further include at least one port for coupling to the reduced pressure source to extract accumulated fluids from the substrate. The port can further include a valve, e.g., a check valve or one-way valve, to prevent backflow of extracted fluids. The port can further include a conduit providing fluid communication between the absorbent material or at least one wicking layer within the chamber and an external fluid receptacle.
In another aspect, the substrate can include at least one removable backing for handling the substrate prior to positioning it in a skin graft harvester. The substrate can further include at least one removable backing for handling the substrate prior to positioning it at a recipient site. For example, the substrate can include at least a first removable backing associated with the base layer for handling the substrate prior to positioning it in a skin graft harvester and a second removable backing for handling the substrate and an associated skin graft prior to positioning it at a recipient site.
In another embodiment, a skin graft transplantation substrate is provided including a base layer, an adhesive, a sealing member, a first wicking layer, a second wicking layer, an absorbent layer, and a conduit interface. The base layer has a periphery surrounding a central portion and a plurality of apertures disposed through the periphery and the central portion, wherein the base layer is adapted to cover the skin graft transplantation site and tissue surrounding the site. The sealing member has a periphery and a central portion, the periphery of the sealing member being positioned proximate the periphery of the base layer such that the central portion of the sealing member and the central portion of the base layer define an enclosure. The first wicking layer and the second wicking layer are each disposed in the enclosure. The absorbent layer is positioned in fluid communication between the first wicking layer and the second wicking layer. A peripheral portion of the first wicking layer is coupled to a peripheral portion of the second wicking layer providing a wicking layer enclosure surrounding the absorbent layer between the first and the second wicking layer. The conduit interface is positioned proximate to the sealing member and in fluid communication with the dressing.
In another aspect, a system is provided for draining a skin transplantation site including a substrate or dressing and a reduced-pressure source. The substrate or dressing is adapted to provide reduced pressure and/or to store fluid extracted from the site. The substrate or dressing includes a base layer, an adhesive, a sealing member, a first wicking layer, a second wicking layer, an absorbent layer, and a conduit interface. The base layer has a periphery surrounding a central portion and a plurality of apertures disposed through the periphery and the central portion. The central portion of the base layer is adapted to be positioned proximate the transplantation site and the periphery of the base layer is adapted to be positioned proximate the tissue surrounding the transplantation site. Further, the periphery of the base layer is adapted to surround the transplantation site, and the apertures in the base layer are adapted to be in fluid communication with site and the tissue surrounding the transplantation site. In certain embodiments, adhesive can be stored or preloaded into apertures in the base layer such that upon placement of the base layer onto the transplantation site, the adhesive is released. (A two-part lower backing can also be employed such that a first (inner) portion of the lower backing is removed when the substrate is joined to a skin graft harvester and a second outer portion of the backing subsequently removed to facilitate peripheral adhesion at the transplantation site.) The sealing member has a periphery and a central portion, the periphery of the sealing member being positioned proximate the periphery of the base layer such that the central portion of the sealing member and the central portion of the base layer define an enclosure. The first wicking layer and the second wicking layer are each disposed in the enclosure. The absorbent layer is positioned in fluid communication between the first wicking layer and the second wicking layer. The conduit interface is positioned proximate to the sealing member and in fluid communication with the dressing. The reduced-pressure source is adapted to be coupled in fluid communication with the conduit interface to provide reduced pressure to the dressing.
In another aspect of the invention, methods are disclosed for fluid management during skin transplantation. The methods can include the steps of contacting at least one skin graft with an absorbent substrate, the substrate comprising a base layer having a surface adapted to contact and engage at least one excised skin graft and a sealing member peripherally joined to the base layer and defining an enclosure therebetween; and an absorbent material disposed within the enclosure; deploying the substrate at a recipient site such that a skin graft that is engaged by the base layer contacts the recipient site; and maintaining the substrate in contact with the recipient site to facilitate transplantation of the graft and removal of fluids.
In another aspect, the methods of the present invention can include maintaining the absorbent substrate at the recipient site, and further, removing excess fluids at the recipient site by extraction into the absorbent material of the substrate. The methods can be practiced by providing a plurality of pores in the base layer to provide a fluid communication path between a recipient site and the absorbent material within the substrate and, optionally, deploying at least one wicking layer within the substrate to distribute fluids captured from a recipient site to different regions of the absorbent material.
In certain embodiments, the methods can further include a step of coupling the substrate to a reduced pressure source to facilitate fluid extraction and, optionally, draining accumulated fluids from the absorbent material into a fluid extraction receptacle or deploying a one-way valve between the absorbent material and the fluid extraction receptacle.
Other aspects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
A more complete understanding of this specification may be obtained by reference to the following detailed description when taken in conjunction with the accompanying drawings wherein:
In the following detailed description of non-limiting, illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. Other embodiments may be utilized and logical, structural, mechanical, electrical, and chemical changes may be made without departing from the scope of this specification. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is not to be taken in a limiting sense, with the scope of the illustrative embodiments being defined by the appended claims.
The term “micrograft” as used herein is intended to encompass skin grafts that have a width or length less than a millimeter, more preferably, less than 100 microns. A micrograft is an excised skin segment having at least one dimension parallel to the skin surface that is less than a millimeter, preferably less than 100 micrometers, more preferably in some applications less than 10 micrometers. The minimum width or length is preferably less than 500 micrometers, preferably less than 100 micrometers or less than 50 micrometers or less than 10 micrometers or less than 1 micrometer. For example, a micrograft can be generally circular, oval or oblong in a plane parallel to the skin surface and have a diameter or major axis that ranges from about 1 millimeter to 0.01 micrometers, or from about 100 micrometers to about 0.1 micrometers, or more preferably from about 50 to 1 micrometers. Micrografts also typically have a depth dimension that extends at least through the epidermis and preferably in some applications encompasses at least one layer of basal cells. The depth can range from about 500 micrometers to about 0.1 micrometers, preferably from about 100 micrometers to about 1 micrometer.
The term “harvesting” as used herein is intended to encompass the removal of one or more skin grafts from an skin graft generating device, such as, for example, a suction blister micrograft generator, as well as the transplantation of such skin grafts and any intermediate steps, such as culturing, expanding, stretching, treating or otherwise preparing a skin graft for transfer to a recipient site.
The terms “generally circular” and “circular” are used interchangeably herein to describe openings that are round, oval or otherwise form closed polygonal shapes having a major dimension (width or diameter) that is less than 5 times the minor dimension (width or diameter) of the shape. Preferably the major dimension is less than 3 times, or less than 2 times, the minor dimension.
The term “about,” as used herein, refers to variations in a numerical quantity that can occur, for example, through measuring or handling procedures in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of compositions or reagents; and the like. Typically, the term “about” as used herein means greater or lesser than the value or range of values stated by 1/10 of the stated values, e.g., ±10%. For instance, a concentration value of about 30% can mean a concentration between 27% and 33%. The term “about” also refers to variations that would be recognized by one skilled in the art as being equivalent so long as such variations do not encompass known values practiced by the prior art. Each value or range of values preceded by the term “about” is also intended to encompass the embodiment of the stated absolute value or range of values. Whether or not modified by the term “about,” quantitative values recited in the claims include equivalents to the recited values, e.g., variations in the numerical quantity of such values that can occur, but would be recognized to be equivalents by a person skilled in the art.
Referring to the drawings,
Additionally,
Additional details on harvesters useful in connection with the present invention can be found in U.S. patent application Ser. No. 13/839,518 filed Mar. 15, 2013; U.S. patent application Ser. No. 13/346,329 filed Jan. 9, 2012; U.S. patent application Ser. No. 13/436,318 also filed Jan. 9, 2012; U.S. patent application Ser. No. 13/014,737 filed Jan. 27, 2011; U.S. patent application Ser. No. 12/851,656 filed Aug. 6, 2010; U.S. patent application Ser. No. 12/851,621 filed Aug. 6, 2010; U.S. patent application Ser. No. 12/851,703 filed Aug. 6, 2010; and U.S. patent application Ser. No. 12/851,682 filed Aug. 6, 2010. The contents of each of the above-referenced related applications are herein incorporated by reference in their entireties.
Returning to
Alternatively, the base layer can be fluid permeable, e.g., composed of a material that has high water permeability in either liquid or vapor form, such as polyurethanes, polyesters, polyvinyl chlorides, copolymers of vinyl chloride and vinyl acetate or vinyl chloride and ethylene, polyolefins, polyamides, polyethylene, polypropylene, silicone or polystyrenes, polyacrylics, polyacrylates, polyvinyl alcohol, and copolymers thereof. Examples of water permeable materials include polyurethane films, such as Ensure-IT dressing (Deseret Medical, Inc.) and POLYSKIN® transparent dressing (Kendall Company, Boston, Mass.).
Various techniques can be employed to increase the permeability or porosity of polymer films, such as the incorporation of inclusions during polymer processing that are subsequently dissolved or evaporated away to leave micro-sized or nano-sized voids, e.g., voids having an average width ranging from about 0.1 nanometers to about 1 millimeter or from about 1 nanometer to about 100 micrometers. In certain embodiments, micro-pores having an average width of about 0.1 micrometers to about 1 millimeter can be desired. In other embodiments, nano-pores having an average size of about 0.1 to about 100 nanometers, preferably about 1 to about 100 nanometers or about 1 to about 10 nanometers, can be advantageous.
In another embodiment, a permeable or porous base layer can be formed from woven or non-woven (e.g., matted) fibers. The fibrous base layer can include microfibers and/or nanofibers. In certain embodiments, microfibers having an average diameter of about 0.1 to about 10 micrometers can be desired. In other embodiments, nanofibers having an average diameter of about 1 to about 100 nanometers, preferably about 20 to about 80 nanometers, although in some instances, fibers with diameters about 1 to about 20 nanometers, can also be advantageous.
In yet another embodiment, the base layer can be a foamed material, such as an open cell polymer foam that is formed through the use of chemical and/or physical blowing agents during polymer processing. The foamed base layer should have a sufficiently open cell structure such that fluid passageways are formed through the full thickness of the foamed base layer to facilitate fluid extraction. The average width of the open cells can range from about 1 nanometer to about 1 millimeter, preferably in some instances from about 10 nanometer to about 100 micrometers, or from about 100 nanometers to 10 micrometers. Foam polymers can have from about 1 to 1000 pores per square inch, preferably in some instances, from about 10 to 100 pores per square inch. Preferred foam polymers can void fractions from about 10 to about 90 percent, or void fractions greater than 20 percent, 30 percent, 40 percent or 50 percent.
The terms “porous” as used herein is intended to encompass not only apertures or holes but also permeable and open cell foam structures as described above.
The base layer 12, in certain embodiments, is preferably a soft material suitable for providing a fluid seal with the skin graft transplantation site as described herein. For example, the base layer 12 may comprise a silicone gel, a soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrenic copolymer gels, a foamed gel, a soft closed cell foam such as polyurethanes and polyolefins, polyurethane, polyolefin, or hydrogenated styrenic copolymers coated with an adhesive described below. The base layer 12 can have a thickness between about 500 microns (μm) and about 1000 microns (μm). In one embodiment, the base layer 12 has a stiffness between about 5 Shore OO and about 80 Shore OO. The base layer 12 can include hydrophobic or hydrophilic materials.
In some embodiments, the base layer 12 may be a hydrophobic-coated material. For example, the base layer 12 may be formed by coating a mesh or porous material, such as, for example, woven, nonwoven, molded, or extruded mesh with a hydrophobic material. The hydrophobic material for the coating may be a soft silicone, for example.
The adhesive 17 used to capture skin grafts and/or adhere the substrate 10 to a patient at the transplantation site may be any medically-acceptable adhesive. For example, the adhesive 17 may comprise an acrylic adhesive, rubber adhesive, high-tack silicone adhesive, polyurethane, or other adhesive substance. In some embodiments, the adhesive 17 may be a pressure-sensitive adhesive comprising an acrylic adhesive with a coating weight of 15 grams/m2 (gsm) to 70 grams/m2 (gsm). The adhesive 17 may be a continuous or a discontinuous layer of material. Discontinuities in the adhesive 17 may be provided by pores 18 in the base layer 12. The apertures in the adhesive may be formed after application of the adhesive to the base layer or by coating the adhesive 17 in patterns on the base layer.
Factors that may be utilized to control the adhesion strength of the substrate 10 may include the diameter and number of the pores 18 in the base layer 12, the thickness of the base layer 12, the thickness and amount of the adhesive 17, and the tackiness of the adhesive 17. An increase in the amount of the adhesive 17 generally corresponds to an increase in the adhesion strength of the substrate 10. Thus, the size and configuration of the adhesive coated portions of the base layer 12, the thickness of the base layer 12, and the amount and tackiness of the adhesive utilized may be varied to provide a desired adhesion strength for the substrate 10. For example, the thickness of the base layer 12 may be about 200 microns, and the adhesive layer 17 may have a thickness of about 30 microns and a tackiness of 2000 grams per 25 centimeter wide strip.
Continuing with
The sealing member 20 may cover the tissue site 6 to provide a fluid seal and a sealed space between the tissue site 6 and the sealing member 20 of the substrate 10. Further, the sealing member 20 may cover tissue, such as a portion of the epidermis 106, surrounding the tissue site 6 to provide the fluid seal.
The sealing member 20 may be formed from any material that allows for a fluid seal. A fluid seal is a seal adequate to maintain reduced pressure at a desired site given the particular reduced pressure source or system involved. The sealing member 20 may comprise, for example, one or more of the following materials: hydrophilic polyurethane; cellulosics; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; hydrophilic silicone elastomers; an INSPIRE 2301 material from Expopack Advanced Coatings of Wrexham, United Kingdom having, for example, an MVTR (inverted cup technique) of 14400 g/m2/24 hours and a thickness of about 30 microns; a thin, uncoated polymer drape; natural rubbers; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; polyurethane (PU); EVA film; co-polyester; silicones; a silicone drape; a 3M Tegaderm® drape; a polyurethane (PU) drape such as one available from Avery Dennison Corporation of Pasadena, Calif.; polyether block polyamide copolymer (PEBAX), for example, from Arkema, France; or other appropriate material.
The sealing member 20 may allow vapor to exit while inhibiting liquids from exiting the sealed space provided by the substrate 10. The sealing member 20 may be a flexible, breathable film having a high MVTR of, for example, at least about 300 g/m2 per 24 hours. The sealing member 20 may comprise a range of medically suitable films having a thickness between about 15 microns (μm) to about 50 microns (μm). In other embodiments, a low or no vapor transfer drape can be used as the sealing member.
The fluid management assembly may be disposed in the enclosure 31 and may include a first wicking layer 26, a second wicking layer 28, and an absorbent layer 24. The absorbent layer 24 may be positioned in fluid communication between the first wicking layer 26 and the second wicking layer 28. The first wicking layer 26 may have a grain structure (not shown) adapted to wick fluid along a surface of the first wicking layer 26. Similarly, the second wicking layer 28 may have a grain structure (not shown) adapted to wick fluid along a surface of the second wicking layer 28. For example, the first and the second wicking layer 26, 28 may wick or otherwise transport fluid in a lateral direction along the surfaces of the first and the second wicking layer 26, 28, respectively. The surfaces of the first and the second wicking layer 26, 28 may be normal relative to the thickness of each of the first and the second wicking layer 26, 28. The wicking of fluid along the first and the second wicking layers 26, 28 may enhance the distribution of the fluid over a surface area of the absorbent layer 24 that may increase absorbent efficiency and resist fluid blockages. Fluid blockages may be caused, for example, by fluid pooling in particular location in the absorbent layer 24 rather than being distributed more uniformly across the absorbent layer 24. The laminate combination of the first and the second wicking layer 26, 28 and the absorbent layer 24 may be adapted as described above to maintain an open structure, resistant to blockage, that can maintain fluid communication with, for example, the tissue site 6.
The substrate 10 may include, without limitation, any number of wicking layers and absorbent layers as desired for treating a particular tissue site. For example, the absorbent layer 24 may be a plurality of absorbent layers 24 positioned in fluid communication between the first wicking layer 26 and the second wicking layer 28 as described above. Further, at least one intermediate wicking layer may be disposed in fluid communication between the plurality of absorbent layers 24. Similar to the absorbent layer 24 described above, the plurality of absorbent layers 24 and the at least one intermediate wicking layer may be positioned within the wicking layer enclosure.
In one embodiment, the absorbent material or layer 24 may be a hydrophilic material adapted to absorb fluid from, for example, the tissue site 6. Materials suitable for the absorbent layer 184 may include Luquafleece® material, Texus FP2326, BASF 402c, Technical Absorbents 2317 available from Technical Absorbents (www.techabsorbents.com), sodium polyacrylate super absorbers, cellulosics (carboxy methyl cellulose and salts such as sodium CMC), or alginates. Materials suitable for the first and second wicking layers 26, 28 may include any material having a grain structure capable of wicking fluid as described herein, such as, for example, Libeltex TDL2 80 gsm.
The substrate 10 can be a pre-laminated structure manufactured at a single location or simply individual layers of material stacked upon one another as described above. Individual layers of the substrate 10 may be bonded or otherwise secured to one another without adversely affecting fluid management by, for example, utilizing a solvent or non-solvent adhesive, or by thermal welding.
In one embodiment, the enclosure 31 defined by the base layer 12 and the sealing member 20 may include an anti-microbial layer. The addition of the anti-microbial agent may reduce the probability of excessive bacterial growth within the dressing 10 to permit the dressing 10 to remain in place for an extended period. The anti-microbial material may be, for example, an additional layer included as a part of the substrate 10 as depicted in
In an alternative embodiment, the base layer and absorbent material can be replaced by a single, unitary element (with or without wicking material) that provides both the skin-contacting and the fluid absorbing functions.
In this context the absorbent material having a skin-contacting surface in lieu of a separate base layer can be a sponge material, e.g., an elastic open pore structured polymer such as cellulose, collagen, gelatin/alginate, polyesters, polyethers, polyvinyl acetates, polyvinyl acetals, polyurethanes, gelatin/hyaluronates or chitosan/hyaluronates, polyvinyl alcohol, and polyacrylates. The sponge material can have a network of interconnected pores for fluid transport, the average cross-sectional width of which can range from 0.05 millimeters (mm) to about 5 millimeters (mm), more preferably from about 0.1 mm to about 1 mm in certain embodiments.
Referring now to
The port 40 can also include one or more filters 47, e.g., an odor filter to inhibit the passage of odors from the tissue site 6 out of the sealed substrate 10, or a hydrophobic filter. The filter 47 can be disposed in the conduit 42 or other suitable location such that fluid communication between the reduced-pressure source 46 and the substrate is provided through the filter 47. In another embodiment, the filters 47 can be positioned in any exit location in the substrate 10, such as an aperture (not shown), that is in fluid communication with the atmosphere or with the reduced-pressure source 46. The filter 47 may also be positioned in any suitable location in the substrate that is in fluid communication with the graft transplantation site 6.
For example, an odor filter 47 may include a carbon material in the form of a layer or particulate, such as a woven carbon cloth filter such as those manufactured by Chemviron Carbon, Ltd. of Lancashire, United Kingdom (www.chemvironcarbon.com). A hydrophobic filter 47 may be comprised of a material that is liquid impermeable and vapor permeable, such as a material manufactured under the designation MMT-314 by W.L. Gore & Associates, Inc. of Newark, Del., United States, or similar materials.
Continuing with
As used herein, “reduced pressure” generally refers to a pressure less than the ambient pressure at a tissue site being subjected to treatment. Typically, this reduced pressure will be less than the atmospheric pressure. The reduced pressure may also be less than a hydrostatic pressure at a tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. While the amount and nature of reduced pressure applied to a tissue site will typically vary according to the application, the reduced pressure will typically be between −5 mmHg and −500 mmHg, and more typically in a therapeutic range between −100 mmHg and −200 mmHg.
The reduced pressure delivered may be constant or varied (e.g., patterned or random) and may be delivered continuously or intermittently. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum. Consistent with the use herein, an increase in reduced pressure or vacuum pressure typically refers to a relative reduction in absolute pressure. An increase in reduced pressure corresponds to a reduction in pressure (more negative relative to ambient pressure) and a decrease in reduced pressure corresponds to an increase in pressure (less negative relative to ambient pressure).
A conduit 42 having an internal lumen may be coupled in fluid communication between the reduced-pressure source 46 and the substrate 10. The conduit interface 43 may be coupled in fluid communication with the dressing and adapted to connect between the conduit 42 and the substrate 10 for providing fluid communication with the reduced-pressure source 46. The conduit interface 43 may be fluidly coupled to the conduit 42 in any suitable manner, such as, for example, by an adhesive, solvent or non-solvent bonding, welding, or interference fit. An aperture (not shown) in the sealing member 20 may provide fluid communication between the substrate and the conduit interface 43. In one embodiment, the conduit 42 may be inserted into the substrate 10 through an aperture (not shown) in the sealing member 20 to provide fluid communication with the reduced-pressure source 46 without utilization of the conduit interface 43. The reduced-pressure source 46 may also be directly coupled in fluid communication with the substrate 10 and/or the sealing member 20. The conduit 42 may be, for example, a flexible polymer tube. A distal end of the conduit 42 may include any one of known couplings for attachment to the reduced-pressure source 46.
Although this specification discloses advantages in the context of certain illustrative, non-limiting embodiments, various changes, substitutions, permutations, and alterations may be made without departing from the scope of the specification as defined by the appended claims. Further, any feature described in connection with any one embodiment may also be applicable to any other embodiment.
Locke, Christopher Brian, Robinson, Timothy Mark, Harper, John R.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
2379574, | |||
2579039, | |||
2721555, | |||
3054404, | |||
3782387, | |||
4345374, | Jan 14 1974 | The Gillette Company | Razor with means to adjust blade geometry |
4600533, | Dec 24 1984 | COHESION TECHNOLOGIES, INC | Collagen membranes for medical use |
4605010, | May 17 1984 | ZIMMER ORTHOPAEDIC SURGICAL PRODUCTS, INC | Pressurizing cuff |
4666447, | Jan 30 1985 | Mentor Corporation | Skin expansion device and method of making the same |
4679324, | Nov 15 1984 | The Gillette Company | Safety razor blades |
4773418, | Dec 22 1982 | Method for manufacturing a transplant | |
4917086, | May 26 1988 | ZIMMER ORTHOPAEDIC SURGICAL PRODUCTS, INC | Dermatome blade assembly |
5015584, | Oct 14 1987 | Board of Regents, The University of Texas System | Epidermal graft system |
5163955, | Jan 24 1991 | Medtronic, Inc | Rapid assembly, concentric mating stent, tissue heart valve with enhanced clamping and tissue alignment |
5386633, | Dec 27 1993 | Hamburger patty knife with blade attachment | |
5433221, | Oct 05 1994 | Windowed self-centering drape for surgical camera | |
5441490, | Jan 09 1991 | SVEDMAN, PAL | Transdermal perfusion of fluids |
5460939, | Apr 18 1986 | ADVANCED BIOHEALING, INC | Temporary living skin replacement |
5476478, | Apr 18 1994 | SMITH, RICK JOEL | Preoperative skin stretching apparatus and method |
5489304, | Apr 19 1994 | SHRINERS HOSPITALS FOR CRIPPLED CHILDREN, A CORPORATION | Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft |
5496339, | May 17 1994 | Universal automated keratectomy apparatus and method | |
5545222, | Aug 12 1991 | Bonutti Skeletal Innovations LLC | Method using human tissue |
5571098, | Nov 01 1994 | General Hospital Corporation, The | Laser surgical devices |
5595570, | Dec 06 1994 | NEW UNITED DEVELOPMENT CORPORATION | Keratome with spring loaded adjustable plate, cutting length adjustment plate, method of cutting a corneal flap, and gauge-mounted bracket for adjusting plate on keratome head |
5686303, | Dec 30 1994 | Reconstructive Technologies | Method of growing vertebrate skin in vitro |
5730717, | Dec 16 1994 | Method and associated device for removing material from body | |
5759193, | Apr 21 1994 | ZIMMER ORTHOPAEDIC SURGICAL PRODUCTS, INC | Single needle skin stretching device |
5792173, | Jul 10 1995 | EDWARDS, STUART D | Wound closure hemostasis device |
5817115, | Dec 04 1995 | BAUSCH & LOMB SURGICAL, INC | Apparatus for resecting corneal tissue |
5888219, | Aug 12 1991 | Bonutti Skeletal Innovations LLC | Method of using human tissue with a tissue press and system |
5914261, | Jun 01 1990 | Regeneron Pharmaceuticals, Inc.; Board of Regents, University of Texas System | Family of MAP2 protein kinases |
5914264, | Dec 30 1994 | Reconstructive Technologies | Apparatus for growing vertebrate skin in vitro |
5921980, | Dec 03 1997 | University of Kentucky Research Foundation; KENTUCKY, UNIVERSITY OF, RESEARCH FOUNDATION | Laser skin graft harvesting apparatus and related method |
5972476, | Nov 21 1997 | Means Industries, Inc.; MEANS INDUSTRIES, INC | Laminated parts and method of making same |
5976163, | Dec 04 1995 | Bausch & Lomb Surgical, Inc. | Apparatus for resecting corneal tissue |
6056738, | Jan 31 1997 | TRANSMEDICA INTERNATIONAL, INC | Interstitial fluid monitoring |
6063094, | Dec 07 1995 | 4 MED LTD | Adjustable skin mesher device and a system for using the same |
6071247, | Jul 31 1997 | KENNEDY, DANIEL L M | Skin blister biopsy apparatus and method |
6071267, | Feb 06 1998 | KCI Licensing, Inc | Medical patient fluid management interface system and method |
6080166, | Dec 05 1995 | DELFI MEDICAL INNOVATIONS INC | Direct linear drive dermatome |
6083236, | Aug 12 1998 | BioVision AG | Keratome method and apparatus |
6248114, | Oct 15 1996 | Burncare B. V. | Method for forming skin grafts |
6254580, | Apr 27 1995 | Suction blister sampling | |
6358260, | Apr 20 1998 | MED-LOGICS, INC | Automatic corneal shaper with two separate drive mechanisms |
6364908, | Oct 15 1996 | Burncare B.V. | Method and instruments for stretching skin grafts |
6402770, | Jun 01 1998 | THORACAR SYSTEMS LLC | Method and apparatus for placing and maintaining a percutaneous tube into a body cavity |
6436078, | Jan 07 1992 | Transdermal perfusion of fluids | |
6585939, | Feb 26 1999 | Beckman Coulter, Inc | Microstructures for use in biological assays and reactions |
6612310, | Jun 22 2000 | GE Medical Systems Global Technology Company, LLC | Windowed medical drape |
6623498, | Feb 10 1999 | SIS Ltd. | Cutting instrument |
6693077, | Feb 14 1995 | Human Genome Sciences, INC | Keratinocyte growth factor-2 |
6800282, | Jun 26 1997 | Smith & Nephew, PLC | Cell culture products |
6860904, | Aug 12 1991 | Bonutti Skeletal Innovations LLC | Method for tissue grafting |
7056327, | Oct 24 1997 | MORIA S A ; BECTON DICKINSON ACCUTECARE, INC | Keratome with suspended stabilized blade, applanator and guided engagement with keratome cutter head |
7078582, | Jan 17 2001 | 3M Innovative Properties Company | Stretch removable adhesive articles and methods |
7137979, | May 31 2003 | ZENO CORPORATION | Methods and devices for the treatment of skin lesions |
7207998, | Aug 12 1998 | BioVision AG | Intracorneal lens placement method and apparatus |
7208006, | Mar 01 2002 | Process and instrument for stretching tissue of skin | |
7244444, | Mar 31 2004 | Cook Medical Technologies LLC | Graft material, stent graft and method |
7513902, | Oct 01 2001 | The Cleveland Clinic Foundation | Skin lesion exciser and skin-closure device therefor |
7540875, | Jun 01 1998 | THORACAR SYSTEMS LLC | Surgical cutting tool with automatically retractable blade assembly |
7625384, | Feb 27 2003 | APPLIED TISSUE TECHNOLOGIES LLC | Method and apparatus for processing dermal tissue |
7651507, | Mar 03 2003 | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | Tissue processing system |
7666134, | Sep 28 2002 | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | System and method for transplantation of dermal tissue |
7666192, | Feb 16 2001 | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | Skin grafting devices and methods |
7708746, | Feb 27 2003 | APPLIED TISSUE TECHNOLOGIES LLC | Method and apparatus for processing dermal tissue |
7727760, | Dec 23 2005 | Industrial Technology Research Institute | Cell colonies dissecting and transplanting apparatus |
7926401, | Mar 03 2003 | KCI Licensing, Inc. | Tissue harvesting device and method |
8002779, | Dec 13 2007 | ZIMMER SURGICAL, INC | Dermatome blade assembly |
8109187, | Mar 03 2003 | KCI Licensing, Inc. | Tissue harvesting device and method |
8162957, | Mar 03 2003 | KCI Licensing, Inc. | Tissue processing system |
8187285, | Feb 27 2003 | APPLIED TISSUE TECHNOLOGIES LLC | Method and apparatus for processing dermal tissue |
8562626, | Aug 06 2010 | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | Devices for harvesting a skin graft |
8617181, | Aug 06 2010 | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | Methods for preparing a skin graft |
8926631, | Aug 06 2010 | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | Methods for preparing a skin graft without culturing or use of biologics |
9173674, | Aug 06 2010 | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | Devices for harvesting a skin graft |
20010029380, | |||
20020052614, | |||
20020092529, | |||
20030009185, | |||
20030069571, | |||
20030212357, | |||
20040097967, | |||
20040172045, | |||
20040186498, | |||
20040215217, | |||
20040225309, | |||
20040230215, | |||
20040237744, | |||
20050038520, | |||
20050076921, | |||
20050101972, | |||
20050221276, | |||
20050234485, | |||
20050244967, | |||
20060079852, | |||
20060141616, | |||
20060173087, | |||
20060258956, | |||
20060271070, | |||
20060287696, | |||
20070183974, | |||
20070255168, | |||
20080146980, | |||
20090085286, | |||
20090099122, | |||
20100012311, | |||
20100042127, | |||
20100121311, | |||
20100145360, | |||
20100152651, | |||
20100152750, | |||
20100286635, | |||
20100310823, | |||
20110009882, | |||
20110077664, | |||
20110251602, | |||
20110264115, | |||
20110282309, | |||
20120021186, | |||
20120035599, | |||
20120035618, | |||
20120035619, | |||
20120035620, | |||
20120041430, | |||
20120125798, | |||
20120136323, | |||
20120172894, | |||
20120197267, | |||
20120201755, | |||
20120201793, | |||
20120244623, | |||
20120271320, | |||
20130041385, | |||
20130145596, | |||
20130158627, | |||
20130204273, | |||
20140277454, | |||
20150127077, | |||
20150182241, | |||
CN101053528, | |||
CN2125374, | |||
CN2596950, | |||
EP99748, | |||
EP1092515, | |||
EP1614404, | |||
EP2837370, | |||
JP2009095476, | |||
SU772544, | |||
WO3093418, | |||
WO1992011879, | |||
WO1995028886, | |||
WO1996018432, | |||
WO1996033768, | |||
WO1997020509, | |||
WO1998016158, | |||
WO2003020333, | |||
WO2003039382, | |||
WO2003049626, | |||
WO2003049783, | |||
WO2003068120, | |||
WO2004071313, | |||
WO2004075764, | |||
WO2004078032, | |||
WO2004105576, | |||
WO2005033273, | |||
WO2005046428, | |||
WO2007034438, | |||
WO2007117488, | |||
WO2010014716, | |||
WO2010036788, | |||
WO2011038326, | |||
WO2011059441, | |||
WO2011075676, | |||
WO2012019094, | |||
WO2012019095, | |||
WO2012019096, | |||
WO2012019098, | |||
WO2012102812, | |||
WO2012145504, | |||
WO20140152319, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Nov 25 2013 | LOCKE, CHRISTOPHER BRIAN | KCI Licensing, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 032439 | /0236 | |
Nov 25 2013 | HARPER, JOHN R | KCI Licensing, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 032439 | /0236 | |
Nov 26 2013 | ROBINSON, TIMOTHY MARK | KCI Licensing, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 032439 | /0236 | |
Mar 14 2014 | KCI Licensing, Inc. | (assignment on the face of the patent) | / | |||
Sep 20 2016 | KCI USA, INC | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | SECOND LIEN SECURITY AGREEMENT | 040098 | /0268 | |
Sep 20 2016 | LifeCell Corporation | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | SECOND LIEN SECURITY AGREEMENT | 040098 | /0268 | |
Sep 20 2016 | KCI Licensing, Inc | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | SECOND LIEN SECURITY AGREEMENT | 040098 | /0268 | |
Oct 06 2016 | KCI Licensing, Inc | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT | 040291 | /0237 | |
Oct 06 2016 | LifeCell Corporation | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT | 040291 | /0237 | |
Oct 06 2016 | KCI USA, INC | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT | 040291 | /0237 | |
Feb 03 2017 | WILMINGTON TRUST | KCI USA, INC | RELEASE OF SECURITY INTEREST REEL FRAME 040098 0268 | 041666 | /0320 | |
Oct 11 2019 | WILMINGTON TRUST, NATIONAL ASSOCIATION | KCI USA, INC | RELEASE OF SECURITY INTEREST IN PATENTS | 050966 | /0547 | |
Oct 11 2019 | WILMINGTON TRUST, NATIONAL ASSOCIATION | KCI Licensing, Inc | RELEASE OF SECURITY INTEREST IN PATENTS | 050966 | /0547 | |
Aug 24 2023 | KCI Licensing, Inc | 3M Innovative Properties Company | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 064730 | /0636 | |
Feb 01 2024 | 3M Innovative Properties Company | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 066432 | /0376 |
Date | Maintenance Fee Events |
Oct 20 2021 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Date | Maintenance Schedule |
May 08 2021 | 4 years fee payment window open |
Nov 08 2021 | 6 months grace period start (w surcharge) |
May 08 2022 | patent expiry (for year 4) |
May 08 2024 | 2 years to revive unintentionally abandoned end. (for year 4) |
May 08 2025 | 8 years fee payment window open |
Nov 08 2025 | 6 months grace period start (w surcharge) |
May 08 2026 | patent expiry (for year 8) |
May 08 2028 | 2 years to revive unintentionally abandoned end. (for year 8) |
May 08 2029 | 12 years fee payment window open |
Nov 08 2029 | 6 months grace period start (w surcharge) |
May 08 2030 | patent expiry (for year 12) |
May 08 2032 | 2 years to revive unintentionally abandoned end. (for year 12) |